Physician profile
Karim Mohamed Al-Azizi
NPI 1457649592
$733,577.55
in general payments reported to CMS, 2019-2025
45 companies · $324K in 2025
The $324K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $26K · 2021: $46K · 2022: $84K · 2023: $71K · 2024: $161K · 2025: $324K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $279K · Travel and Lodging: $117K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $52K · Food and Beverage: $43K · Honoraria: $37K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Grant: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $279,495.25 |
| Travel and Lodging | $116,606.20 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $52,300.00 |
| Food and Beverage | $42,601.05 |
| Honoraria | $37,022.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,781.50 |
| Grant | $1,373.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $220,228.59 | 2019-2025 | Igt Devices Undivided, (9520) Igt Devices Undivided, (Bh4) Igt Devices Undivided |
| Edwards Lifesciences Corporation | $196,993.10 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shockwave Medical, INC | $145,746.11 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Medtronic, INC. | $57,611.87 | 2021-2025 | Ffrangio, Onyx Frontier, Corevalve Evolut R |
| Abbott Laboratories | $49,793.36 | 2019-2025 | Amplatzer Amulet, Mitraclip, Triclip |
| Biosense Webster, INC. | $16,337.13 | 2024-2025 | Carto 3, Nuvision Ice Catheter, Qdot Micro |
| Boston Scientific Corporation | $14,545.86 | 2019-2025 | General - Balloons, Avvigo Guidance System, Watchman Flx |
| Cathworks, INC. | $10,458.74 | 2022-2025 | Ffrangio |
| Biotronik INC. | $4,636.10 | 2024-2025 | Orsiro Mission, Pk Papyrus, Nhancer Rx |
| Heartflow, INC. | $4,170.86 | 2020-2025 | Ffrct |
| Abiomed | $2,998.94 | 2019-2025 | Impella |
| Spectrawave, INC | $2,590.02 | 2024-2025 | Starlight Imaging Catheter, Hypervue Imaging System |
| Medtronic Vascular, INC. | $1,296.35 | 2019-2020 | |
| Zoll Circulation INC | $1,200.00 | 2024 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Nipro Medical Corporation | $1,100.00 | 2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $531.13 | 2023-2025 | Guideliner, Orsiro Mission, Manta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $522.31 | 2019-2020 | |
| Recor Medical INC | $317.11 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Angiodynamics, INC. | $274.99 | 2022-2025 | Alphavac |
| Jenavalve Technology, INC. | $256.50 | 2025 | |
| Inari Medical, INC. | $207.61 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ekos Corporation | $172.10 | 2019 | |
| Penumbra, INC. | $163.96 | 2025 | Penumbra System |
| Terumo Medical Corporation | $149.89 | 2025 | Glidesheath Slender, Angio-Seal |
| E.R. Squibb & Sons, L.L.C. | $147.55 | 2024-2025 | Eliquis, Camzyos |
| Regeneron Pharmaceuticals, INC. | $122.81 | 2019 | |
| United Therapeutics Corporation | $112.20 | 2019 | |
| Esperion Therapeutics, INC. | $108.18 | 2020-2023 | Nexletol |
| Novo Nordisk INC | $104.86 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $102.54 | 2022-2023 | Verquvo |
| Chiesi USA, INC. | $100.77 | 2023 | |
| Astellas Pharma US INC | $94.87 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $61.61 | 2023 | Optimizer |
| Amgen INC. | $45.16 | 2023-2024 | Repatha |
| Stryker Corporation | $44.04 | 2025 | Flowstasis |
| Novartis Pharmaceuticals Corporation | $40.90 | 2020-2021 | |
| Inspire Medical Systems, INC. | $36.44 | 2025 | Inspire |
| Asahi Intecc USA, INC. | $30.71 | 2023 | Asahi Ptca Guide Wire |
| Kiniksa Pharmaceuticals International, Plc | $20.72 | 2024 | Arcalyst |
| Cordis US Corp. | $19.97 | 2025 | Selution Slr Ptca |
| Itamar Medical INC | $19.00 | 2022 | |
| Amarin Pharma, INC. | $18.07 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.58 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $15.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65.95 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Al-Azizi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.